Italia markets open in 6 hours 1 minute

GW Pharmaceuticals plc (GWPH)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
127,61-1,72 (-1,33%)
Alla chiusura: 4:00PM EST

127,61 0,00 (0,00%)
Dopo ore: 4:04PM EST

GW Pharmaceuticals plc

Sovereign House
Vision Park Chivers Way Histon
Cambridge CB24 9BZ
United Kingdom
44 1223 266 800
http://www.gwpharm.com

Settore/iHealthcare
SettoreDrug Manufacturers—General
Impiegati a tempo pieno901

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Justin D. GoverCEO & Exec. Director1,19M4,11M1971
Mr. Scott M. GiacobelloChief Financial Officer743,33k253,81k1970
Mr. Douglas B. SnyderChief Legal Officer787,02k244,37k1964
Dr. Volker Knappertz M.D., D.Sc.Chief Medical Officer830,47k288,48k1965
Mr. Christopher John ToveyChief Operating OfficerN/DN/D1965
Mr. Stephen D. SchultzVP of Investor RelationsN/DN/DN/D
Ms. Tina St. LegerChief HR OfficerN/DN/DN/D
Prof. Ben WhalleyHead of Discovery ResearchN/DN/DN/D
Mr. Darren S. ClineU.S. Chief Commercial OfficerN/DN/D1964
Mr. Adam David GeorgeMD of UK & Company Sec.N/DN/D1970
Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di GW Pharmaceuticals plc al 1 novembre 2019 è 4. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 5; diritti degli azionisti: 4; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.